Review



tnfr1 antagonist r7050  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Tocris tnfr1 antagonist r7050
    Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
    Tnfr1 Antagonist R7050, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tnfr1 antagonist r7050/product/Tocris
    Average 90 stars, based on 1 article reviews
    tnfr1 antagonist r7050 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Retinal response to systemic inflammation differs between sexes and neurons"

    Article Title: Retinal response to systemic inflammation differs between sexes and neurons

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2024.1340013

    Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
    Figure Legend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

    Techniques Used: Injection, Comparison

    Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).
    Figure Legend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

    Techniques Used: Control, Comparison



    Similar Products

    tnfr1 antagonist r7050  (Tocris)
    90
    Tocris tnfr1 antagonist r7050
    Antagonism of <t>TNFR1</t> and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.
    Tnfr1 Antagonist R7050, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tnfr1 antagonist r7050/product/Tocris
    Average 90 stars, based on 1 article reviews
    tnfr1 antagonist r7050 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

    Journal: Frontiers in Immunology

    Article Title: Retinal response to systemic inflammation differs between sexes and neurons

    doi: 10.3389/fimmu.2024.1340013

    Figure Lengend Snippet: Antagonism of TNFR1 and P2X7R rescues RGCs from systemic inflammation. (A) Isodensity maps showing the distribution of Brn3a + RGCs in retinas of intact male mice and mice treated with LPS+vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. Retinas were analysed 7 days after the injection of LPS. (B) Column graph showing the mean total number ± SD of Brn3a + RGCs the same groups. *Significant vs. intact (*** p <0.001; **** p <0.0001); σ Significant between groups ( σ p <0.05; σσσ p <0.001; σσσσ p <0.0001). One-way ANOVA within sexes, post-hoc Tukey’s test. (C) Column graph showing the averaged percentage ± SD of Brn3a + RGCs in the same groups as before with respect to intact retinas (100%). *Significant differences between females and males (** p <0.01; *** p <0.001; Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p <0.0001). F: females, M: males. I: intact, V: vehicle.

    Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

    Techniques: Injection, Comparison

    Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

    Journal: Frontiers in Immunology

    Article Title: Retinal response to systemic inflammation differs between sexes and neurons

    doi: 10.3389/fimmu.2024.1340013

    Figure Lengend Snippet: Transient impairment of retinal functionality after systemic inflammation: effect of TNFR1 and P2X7R antagonism. (A) Electroretinographic waves from female and male mice recorded before (PRE) and 3 and 7 days after being treated with LPS + vehicle, LPS and TNFR1 antagonist (αTNFR1), LPS and P2X7R antagonist (αP2X7R), and LPS and αP2X7R + αTNFR1. (B) ERG quantification bar graphs showing the mean wave amplitude (µV ± SD). Control amplitudes are baseline recordings (pre). * vs. baseline values (* p <0.05; ** p <0.01***; p <0.001; **** p <0.0001); φ 3 rd vs. 7 th day within the same group ( φφφ p <0.001; φφφφ p <0.0001). σ Between different groups ( σ p <0.05; σσ p <0.01; σσσ p <0.001; σσσσ p <0.0001). † p <0.001 females vs. males at the same time point and treatment. Two-way ANOVA Šidák’s multiple comparison test (treatment p <0.0001; sex p >0.05).

    Article Snippet: Madrid, Spain] and TNFR1 antagonist [12 mg/kg i.p. in 5% of DMSO-saline; R7050, Tocris Bioscience; Bio-Techne R&D Systems, Madrid, Spain], as previously published , were both injected intraperitoneally in a final volume of 200 μL.

    Techniques: Control, Comparison